Recordati stock trades slightly lower as takeover offer period advances

Recordati stock remains in focus as investors track the progress of the ongoing all-share takeover offer, with the share price edging lower in the FTSE MIB while acceptance levels in the bid period gradually build.

Recordati (ISIN IT0003828271) stock traded at 52.15 euros on Borsa Italiana on September 2, 2026, down from a previous reference price of 52.35 euros, corresponding to a modest daily decline of about 0.4 percent according to FTSE MIB price tables from Borsa Italiana and data relayed by a European stock portal. The Italian pharmaceutical group remains under the spotlight as an all-share takeover offer and broader private equity interest continue to frame investor expectations for the company’s future ownership and valuation.

Takeover offer period and acceptance figures

The central corporate catalyst for Recordati stock at the moment is a voluntary public tender offer for all ordinary shares launched by Respighi BidCo, a vehicle backed by CVC and GBL, with the offer period running from August 31, 2026 to October 15, 2026 according to a market update published by Teleborsa and simultaneously highlighted in the notices section of Borsa Italiana. The Italian market report states that on September 2, 2026, 325 acceptance requests were submitted, bringing cumulative tenders to 2,531 shares, which Teleborsa calculates as representing 0.001275% of the total instruments targeted by the offer. While this acceptance rate is still very low compared with the full free float, it nevertheless provides investors with an early numerical indication of shareholder engagement with the bid process as the timetable unfolds.

In the same Teleborsa update, the trading snapshot for Recordati Ord at 17:35 on September 2, 2026 shows a last transaction price of 51.90 euros, a daily percentage change of minus 0.86 percent, an intraday low of 51.90 euros and an intraday high of 52.60 euros, with an opening price of 52.30 euros on Borsa Italiana. This intraday profile positions the closing level slightly below the intraday high and highlights a moderate downward move over the trading session, which is consistent with the FTSE MIB performance overview where Recordati is recorded with a last value of 52.15 euros, a reference price of 52.35 euros and a percentage change line of minus 0.38 percent. Across these two snapshots, investors can see that the share has moved within roughly a 0.4 to 0.9 percent negative range versus the prior price level, a small decline that unfolds as the takeover offer continues but without a dramatic dislocation.

Bid size, valuation framing and investor perspective

Beyond the mechanics of the acceptance period, market commentary continues to reference private equity interest in Recordati, including a proposal where a consortium led by CVC Capital Partners has discussed a bid valued at about 12.4 billion dollars to take the Italian drugmaker private according to a summary carried by a US financial portal and cited in recent market coverage. That indicative valuation figure, even though not all details are formally disclosed in the Italian tender documentation, provides investors with a broad reference scale for the enterprise value that financial sponsors are willing to consider, and therefore helps frame how the current equity market capitalization compares against the implied transaction benchmark.

For shareholders comparing the offer context with day-to-day trading data, the FTSE MIB performance table dated September 2, 2026 shows Recordati Ord as an actively traded constituent of the index, and the modest daily decline of 0.38 percent from 52.35 to 52.15 euros reported by Borsa Italiana suggests that the share price is drifting but not yet reacting with large spikes or drops as acceptance figures trickle in. From an investor perspective, the numerical relationship between the all-share bid valuation and the prevailing market price is a central factor in assessing whether tendering shares into the offer or holding for potential future developments is attractive, and the fact that early acceptance numbers currently represent only around 0.001275% of the targeted instruments underscores that most shareholders are still waiting to see how the situation develops.

Recordati’s business and pharmaceutical portfolio

Recordati is an Italy based pharmaceutical group focusing on prescription medicines, specialty and rare disease products, and a range of targeted therapies that support chronic and acute conditions across several therapeutic areas. Over the last reporting cycles, the company has built a portfolio that includes cardiology and hypertension treatments, gastroenterology medicines, urology and pain management solutions, as well as rare disease therapies marketed through its Recordati Rare Diseases division. These product lines, which are documented in company materials and investor presentations on the Recordati investor relations site, underpin the group’s recurring revenue base and help explain why the business is perceived as relatively defensive within the healthcare segment of the FTSE MIB.

Within rare diseases, Recordati has steadily expanded its presence with orphan therapies distributed in multiple countries, often addressing conditions such as acromegaly and other endocrine disorders where specialized treatment algorithms and personalized care models are evolving. Educational resources and professional discussions around personalized care in acromegaly published in early September 2026, for example by medical organizations and patient focused platforms, illustrate how tailored treatment pathways and updated therapeutic algorithms are gaining importance for clinicians, a trend that indirectly supports demand for specialized medicines from providers like Recordati. For investors, this focus on therapeutically differentiated and often less commoditized drugs can be an important qualitative factor when assessing long term margin resilience and pricing power compared with more generic oriented peers.

Stock level, trading venue and investor takeaway

Recordati shares trade on Borsa Italiana as Recordati Ord and form part of the FTSE MIB index, giving the stock a central role in Italian blue chip healthcare exposure for both domestic and international investors tracking the benchmark. According to the FTSE MIB performance overview dated September 2, 2026, the last recorded value of 52.15 euros in that table, together with the reference price of 52.35 euros and the intraday data from Teleborsa showing a 51.90 to 52.60 euros range, places the stock moderately below the immediate prior price but within a relatively tight intraday corridor. As the takeover offer period between August 31 and October 15, 2026 progresses, market participants are likely to compare these trading levels with the implied valuation of the private equity proposal and with Recordati’s underlying earnings power to decide whether the current risk reward profile is attractive.

Recordati stock at a glance

• Company: Recordati S.p.A.
• ISIN: IT0003828271
• Ticker: RECI
• Trading venue: Borsa Italiana (FTSE MIB)
• Price (as of September 2, 2026): 52.15 euros
• Market capitalization: Not specified (based on latest available price)
• Sector / Industry: Pharmaceuticals / Healthcare
• Index membership: FTSE MIB